
What happened
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) set terms for an underwritten public offering of 11,538,462 common shares at $13.00 apiece. The financing would add cash to the cancer drug developer and dilute shareholders who do not buy any of the new stock.
SELLAS expects the base sale to generate $150 million before underwriting discounts, commissions and offering expenses. The company is issuing all the stock in the deal, so the proceeds would go to SELLAS rather than to selling shareholders.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Expected base gross proceeds | $150 million | SELLAS pricing release | |
| Base offering size | 11,538,462 shares | SELLAS pricing release | |
| Public offering price | $13.00 per share | SELLAS pricing release | |
| Underwriters’ option cap | Up to 1,730,769 shares | SELLAS pricing release | |
| Expected net proceeds with full option exercise | About $161.8 million | SEC 8-K |
Read more: SELLAS Life Sciences Group (SLS) company research
Why it matters
The underwriters can expand the sale beyond the base deal. They have a 30-day option to buy up to 1,730,769 additional shares at the public offering price, less underwriting discounts and commissions. Full exercise would increase the number of shares sold by 15.0% over the base offering priced on Nov. 18, OptimistFi calculates.
The larger share count is built into the company’s estimate of net proceeds. SELLAS expects about $161.8 million after underwriting discounts, commissions and estimated offering expenses if the underwriters exercise the option in full. The option therefore gives the underwriters control over whether SELLAS sells additional common shares on those terms.
The business behind the financing is still developing cancer treatments. Its lead candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in multiple tumor types. SELLAS is also developing SLS009, known as tambiciclib, for patients with acute myeloid leukemia and unfavorable prognostic factors.
OptimistFi views the deal as mixed because it trades a larger share count for more cash to pursue clinical and regulatory progress. The payoff for holders still depends on whether the drug programs produce evidence strong enough to support a partnership or a commercial launch.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
SELLAS expects the offering to close on or about Nov. 20 if customary conditions are met. Closing would secure the base financing, while any additional proceeds would depend on the underwriters exercising their option.
More from OptimistFi
- SLS stock: research and coverage of SELLAS Life Sciences Group
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- Top perps movers today: stocks, commodities, FX and indices
- Open interest live: crypto and stock perps by exchange
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
Sources
- SELLAS pricing release — Nov. 18 announcement giving the offering price, base gross proceeds and underwriter option.
- SEC 8-K — Current report describing the underwriting agreement, conditional net proceeds and expected closing.
Explore OptimistFi research on SELLAS Life Sciences Group, Inc.: https://optimistfi.com/stocks/SLS
Browse SELLAS Life Sciences Group, Inc. company coverage and explore the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
Find available research on the SELLAS Life Sciences Group, Inc. company page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
